Notes on Parky<\/p>\n
parkinsons-treatment-29399.com<\/a><\/p>\n Hypokinesia<\/a><\/p>\n cParkinson’s disease<\/a><\/p>\n https:\/\/en.m.wikipedia.org\/wiki\/Swallowing<\/a><\/p>\n https:\/\/en.m.wikipedia.org\/wiki\/Parkinson%27s_disease_dementia<\/a><\/p>\n https:\/\/www.mayoclinic.org\/diseases-conditions\/parkinsons-disease\/diagnosis-treatment\/drc-20376062<\/a><\/p>\n \u00a0 <\/span>>> Alpha-synuclein clumps are a hallmark sign of Parkinson’s disease. The test accurately identified people with Parkinson’s disease 87.7% of the time.\u00a0 <\/span>..The test is called an alpha-synuclein seed amplification assay<\/em><\/strong>.<\/p>\n Levodopa, the most effective Parkinson’s disease medicine, is a natural chemical that passes into the brain and is converted to dopamine.\u00a0<\/span><\/p>\n Mayo Clinic specialists study genetics, diagnosis and treatment options for people with Parkinson’s disease and other movement disorders. You may have the opportunity to participate in research\u00a0 <\/span>studies and clinical<\/p>\n Watch Mayo Clinic neurologist J. Eric Ahlskog, M.D., Ph.D., describe Parkinson’s disease treatment on YouTube.<\/p>\n https:\/\/www.mayoclinic.org\/drugs-supplements\/carbidopa-and-levodopa-oral-route\/before-using\/drg-20095211<\/a> \u00a0 \u00a0<\/span><\/p>\n https:\/\/en.wikipedia.org\/wiki\/Substantia_nigra<\/a><\/p>\n The substantia nigra is an important player in brain function, in particular, in eye movement<\/a>, motor planning<\/a>, reward-seeking<\/a>, learning<\/a>, and addiction<\/a>.!!!!<\/p>\n Pars compacta \/SNpc : Parkinson’s disease<\/a> is characterized by the death of dopaminergic neurons in this region.[1]<\/p>\n There’s also Cannabinoidergic, or cannabinergic, means “working on the endocannabinoid<\/a> neurotransmitters<\/a>“. As with terms such as dopaminergic<\/a> and serotonergic<\/a>, related proteins and cellular components involved endocannabinoid signaling, such as the cannabinoid (CB1) receptor<\/a>, as well as exogenous compounds, such as phytocannabinoids<\/a> or other cannabinoids<\/a> which modulate the activity of endocannabinoid system<\/a>, can be described as cannabinoidergic.[1]<\/p>\n https:\/\/en.m.wikipedia.org\/wiki\/Basal_ganglia<\/a><\/p>\n Degeneration of pigmented neurons in this region [SN] is the principal pathology<\/a> that underlies Parkinson’s disease<\/a> and this depigmentation can be visualized in vivo with Neuromelanin MRI.[9]\u00a0<\/span><\/p>\n https:\/\/en.m.wikipedia.org\/wiki\/Cannabinoid<\/a><\/p>\n CBN is thought to interact with other kinds of neurotransmission<\/a> (e.g., dopaminergic, serotonergic, cholinergic, and noradrenergic).<\/p>\n https:\/\/www.instagram.com\/reel\/CxONyjHrjDA\/?igshid=MzRlODBiNWFlZA==<\/a><\/p>\n the current opinion in pharmacology is that dopamine instead confers motivational salience<\/a>;[6][7][8]\u00a0<\/span><\/p>\n The blood\u2013brain barrier (BBB) is a highly selective semipermeable<\/a> border of endothelial cells<\/a> that regulates the transfer of solutes and chemicals between the circulatory system<\/a> and the central nervous system<\/a>, thus protecting the brain<\/a> from harmful or unwanted substances in the blood<\/a>.[1]<\/p>\n l-DOPA crosses the protective blood\u2013brain barrier<\/a>, whereas dopamine<\/a> itself cannot.[7]\u00a0<\/span>\u00a0<\/span><\/p>\n To bypass these effects, it is standard clinical practice to coadminister (with l-DOPA) a peripheral DOPA decarboxylase inhibitor<\/a> (DDCI) such as carbidopa<\/a> (medicines containing carbidopa<\/p>\n In work that earned him a Nobel Prize<\/a> in 2000, Swedish<\/a> scientist Arvid Carlsson<\/a> first showed in the 1950s that administering l-DOPA to animals with drug-induced (reserpine<\/a>) Parkinsonian symptoms<\/a> caused a reduction in the intensity of the animals’ symptoms.\u00a0<\/span><\/p>\n https:\/\/en.m.wikipedia.org\/wiki\/Neuropsychopharmacology<\/a><\/p>\n As a consequence, high levels of dopamine lead to high levels of motor activity and impulsive behavior<\/a>; low levels of dopamine lead to torpor<\/a> and slowed reactions.[50]<\/p>\n Recent advances have demonstrated that glial cells, specifically microglia and astroglia, are involved in several neurodegenerative diseases including Amyotrophic lateral sclerosis (ALS), Epilepsy, Parkinson’s disease (PD), Alzheimer’s disease (AD), and ..<\/p>\n